市場調查報告書
商品編碼
1452978
全球生命科學分析軟體市場 2024-2031Global Life Science Analytics Software Market 2024-2031 |
預計全球生命科學分析軟體市場在預測期內(2024-2031 年)CAGR將達到 13.3%。分析軟體在臨床試驗和設計應用中的日益採用是支持全球市場成長的關鍵因素。市場參與者正在使用分析軟體,透過促進更定量、可靠和協作的臨床試驗設計方法來加速新藥的發現。市場參與者也專注於引入生命科學分析軟體解決方案,以進一步促進市場成長。例如,2023 年 2 月,生命科學領域的統計軟體和高級分析供應商 Cytel Inc. 與 GSK 合作部署了臨床策略平台 Solara。透過使用該平台,葛蘭素史克能夠有效協調試驗目標,管理試驗不確定性,並創建經過壓力測試的臨床試驗設計,從而節省成本和時間。該軟體的高成本會限制其市場成長。
全球生命科學分析軟體市場按組件、交付模型和應用程式進行細分。根據組件,市場分為服務和軟體。根據交付模式,市場分為本地模式和按需模式。此外,根據應用,市場分為研發、臨床試驗、銷售和行銷、供應鏈最佳化、藥物警戒和其他(監管合規)。在這些組件中,由於在藥物發現和驗證、實驗室管理、運行臨床試驗和創建新醫療設備方面的應用不斷增加,預計軟體細分市場將佔據相當大的市場佔有率。
在這些應用中,臨床試驗細分市場預計將在全球生命科學分析軟體市場中佔據相當大的佔有率。這一細分市場的成長歸因於臨床試驗中擴大採用生命科學分析解決方案,包括病理檢測和創建可行的治療方案,拓寬了患者選擇的界限,快速對不同方面進行分類,並協助研究人員更準確地識別患有以下疾病的個體:符合涵蓋和排除標準。各種平台提供人工智慧和機器學習增強的軟體解決方案,以自動化關鍵的臨床開發程序,並在一個地方提供試驗操作和患者進展的深入概述。例如,2023 年 6 月,Saama 推出了人工智慧驅動的資料平台,以加速臨床開發。基於 SaaS 的產品的統一平台與其現有的客製化解決方案和服務組合相配合。
全球生命科學分析軟體市場根據地理位置進一步細分,包括北美(美國和加拿大)、歐洲(英國、義大利、西班牙、德國、法國和歐洲其他地區)、亞太地區(印度、中國) 、日本、韓國和亞洲其他地區),以及世界其他地區(中東和非洲以及拉丁美洲。其中,亞太地區預計將在全球市場中呈現最高的CAGR。投資不斷增加在醫療保健IT領域,醫療保健基礎設施的建設、主要競爭對手的出現以及臨床試驗投資的增加是區域市場成長的關鍵因素。
在所有地區中,北美地區佔據全球市場的主要佔有率。區域佔有率歸因於擴大採用分析解決方案來處理大量複雜資料並產生深入的見解,從而改善精準醫學和臨床試驗的整體解決方案,推動市場的成長。醫療保健公司提供分析解決方案,用於在整個治療的各個階段發展患者的觀點。使用統一資料並具有一套全面的分析和機器學習功能的單一平台。例如,2022 年 3 月,Databricks 為醫療保健和生命科學產業的組織推出了產業 Lakehouse 平台。借助用於資料管理、分析和疾病預測、醫學影像分類和生物標記發現等先進人工智慧用例的單一平台,醫療保健組織可以兌現精準醫療的承諾。
服務生命科學分析軟體市場的主要公司包括 Cognizant Technology Solutions Corp.、IQVIA Inc.、Microsoft Corp.、Oracle Corp.、Salesforce, Inc. 等。市場參與者透過各種策略(包括併購、合作、合作、融資和新產品發布),為市場成長做出了巨大貢獻,以保持市場競爭力。例如,2022 年 1 月,Francisco 收購了 IBM 公司廣泛的分析產品和資料集,例如臨床開發、影像軟體、社會專案管理、健康洞察和 Micromedex。
Global Life Science Analytics Software Market Size, Share & Trends Analysis Report by Component (Services and Software), by Delivery Model (On-Premise Model and On-Demand Model), and by Application (Research & Development, Clinical Trials, Sales & Marketing, Supply Chain Optimization, Pharmacovigilance, and Others), Forecast Period (2024-2031)
The global life science analytics software market is anticipated to grow at a significant CAGR of 13.3% during the forecast period (2024-2031). The growing adoption of analytics software in clinical trial and design applications is the key factor supporting the growth of the market globally. Analytical software is being used by market players to speed up the discovery of new medications by facilitating a more quantitative, reliable, and collaborative approach to clinical trial design. The market players are also focusing on introducing life science analytics software solutions that further bolster the market growth. For instance, in February 2023, Cytel Inc., a statistical software and advanced analytics provider in life sciences partnered with GSK to deploy the clinical strategy platform Solara. With the use of the platform, GSK is able to effectively coordinate trial objectives, manage trial uncertainties, and create pressure-tested clinical trial designs that save costs and time. The high cost of this software can restrain their market growth.
The global life science analytics software market is segmented on the component, delivery model, and application. Based on the component, the market is sub-segmented into services and software. Based on the delivery model, the market is sub-segmented into the on-premise model and on-demand model. Further, based on application, the market is sub-segmented in research & development, clinical trials, sales & marketing, supply chain optimization, pharmacovigilance, and others (regulatory compliance). Among the components, the software sub-segment is anticipated to hold a considerable share of the market owing to the increasing application in drug discovery and validation, laboratory administration, running clinical trials, and creating new medical devices.
Among the applications, the clinical trials sub-segment is expected to hold a considerable share of the global life science analytics software market. The segmental growth is attributed to the increasing adoption of life science analytics solutions in clinical trials that include pathology detection and the creation of viable treatment options broadening the boundaries for patient selection, quickly sorting through different aspects, and assisting researchers in more precisely identifying individuals who meet inclusion and exclusion criteria. Various Platforms offer AI and ML-enhanced software solutions to automate critical clinical development procedures and offer an in-depth overview of trial operations and patient progress in one place. For instance, in June 2023, Saama introduced an AI-driven data platform to accelerate clinical development. The unified platform of SaaS-based products to accompany its existing portfolio of customized solutions and services.
The global life science analytics software market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia-Pacific is anticipated to exhibit the highest CAGR in the global market. The increasing investments in healthcare IT, building healthcare infrastructure, the emergence of major competitors, and rising investment in clinical trials are key contributing factors to the regional market growth.
Among all regions, the North American region holds the major share of the global market. Regional share is attributed to the increasing adoption of analytics solutions to process large volumes of complex data and produce in-depth insights, thereby improving the overall solution for precision medicine and clinical trials driving the growth of the market. Healthcare companies provide analytics solutions for developing patient perspectives throughout all stages of treatment. Using a single platform that unifies data and has a comprehensive set of analytics and machine learning features. For instance, in March 2022, Databricks launched the industry's lakehouse platform for organizations across the healthcare and life sciences industries. With a single platform for data management, analytics, and advanced AI use cases like disease prediction, medical image classification, and biomarker discovery, healthcare organizations can deliver on the promise of precision medicine.
The major companies serving the life science analytics software market include Cognizant Technology Solutions Corp., IQVIA Inc., Microsoft Corp., Oracle Corp., Salesforce, Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2022, Francisco acquired IBM Corp.'s wide range of analytic products and data sets, such as clinical development, imaging software, social program management, health insights, and Micromedex.